丹红注射液治疗心脏X综合征的临床疗效

目的观察常规治疗基础上加用丹红注射液治疗心脏X综合征(CSX)患者的近期临床疗效。方法选择CSX患者60例,随机分为观察组(n=30)和对照组(n=30),对照组给予常规治疗,观察组在常规治疗基础上加用丹红注射液治疗,治疗10 d,在治疗前后观察患者的临床疗效,包括心绞痛的发作情况、心电图及运动负荷试验的变化情况,以及血清中内皮素-1(ET-1)、血栓调节蛋白(TM)及选择素-E(Es)的水平。结果观察组与对照组胸痛症状缓解总有效率分别为93.33%vs.73.33%;心电图改善总有效率分别为83.33%vs.56.67%,差异均有统计学意义(P0.05)。观察组与对照组运动负荷试验中运动总时间分别为(486.9±83.0)s vs.(438.3±85.6)s;从运动开始至ST段压低1 mm的时间分别为(351.9±69.2)s vs.(310.7±79.2)s,观察组患者运动负荷改善情况优于对照组,差异具有统计学意义(P0.05)。观察组与对照组治疗前血清ET-1、TM、Es水平无统计学差异(P0.05);治疗后两组血清ET-1水平分别为(54.58±7.95)ng/L vs.(76.21±1.78)ng/L;TM水平分别为(7.01±1.49)μg/L vs.(11.10±1.68)μg/L;Es水平分别为(7.50±2.71)ng/m L vs.(10.71±3.56)ng/m L,差异均具有统计学意义(P0.01)。两组均未见不良反应发生。结论丹红注射液能够改善心脏X综合征患者临床症状,降低CSX患者血清ET-1、TM及Es水平。

Clinical efficacy of Danhong Injection on cardiac syndrome X

Objective To observe the short-term clinical efficacy of routine treatment combining Danhong Injection on cardiac syndrome X （CSX）. Methods The patients （n=60） were randomly divided into observation group and control group （each n=30）. The control group was treated with routine treatment, and observation group was treated with routine treatment combining Danhong Injection for 10 d. The clinical efficacy was observed before and after treatment, including attack of angina, changes of electrocardiogram （ECG） and treadmill exercise test （TET）, and levels of serum endothelin-1 （ET-1）, thrombomodulin （TM） and E-selectin （Es）. Results The total effective rate of chest pain relief was 93.33%in observation group and 73.33%in control group, and total effective rate of ECG relief was 83.33%in observation group and 56.67%in control group （P〈0.05）. In TET, the total exercise time was （486.9±83.0） s in observation group and （438.3±85.6） s in control group, and the time from exercise beginning to ST-segment lowered by 1 mm was （351.9±69.2） s in observation group and （310.7±79.2） s in control group （P〈0.05）. The levels of ET-1, TM and Es had no statistical difference between 2 groups before treatment （P＆gt;0.05）. After treatment, ET-1 （54.58±7.95） ng/L vs. （76.21±1.78） ng/L, TM （7.01±1.49）μg/L vs. （11.10±1.68）μg/L and Es （7.50±2.71） ng/mL vs. （10.71±3.56） ng/mL had statistical difference between 2 groups （P〈0.01）. There were no adverse reactions observed in 2 groups. Conclusion Danhong Injection can relieve the clinical symptoms and reduce levels of ET-1, TM and Es in patients with CSX.